⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11342125 | 0.81 | LMNA (0.36) | — | |
| SCHEMBL210049 | 0.78 | — | — | |
| SCHEMBL2746569 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL27575069 | 0.75 | — | — | |
| SCHEMBL2746559 | 0.74 | CRBN (0.52) | — | |
| SCHEMBL2746471 | 0.73 | — | — | |
| SCHEMBL9259256 | 0.72 | TDP1 (0.63) | — | |
| SCHEMBL2746181 | 0.70 | TAS2R38 (0.44) | — | |
| SCHEMBL2239024 | 0.69 | — | — | |
| Alcohol SCHEMBL11338702 | 0.69 | TGFBR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072886-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | claimed |
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | claimed |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2016-05-19 | — | — | US | claimed |
| US-9321727-B2 | Pyridine derivatives as agonists of the CB2 receptor | HOFFMANN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-9290451-B2 | — | — | 2016-03-22 | — | — | US | claimed |
| EP-2718266-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168350-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |